Sensus Healthcare, Inc. Stock

Equities

SRTS

US81728J1097

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:00:00 2024-06-14 pm EDT 5-day change 1st Jan Change
5.3 USD -1.49% Intraday chart for Sensus Healthcare, Inc. -3.81% +124.58%
Sales 2024 * 34.28M Sales 2025 * 41.1M Capitalization 86.88M
Net income 2024 * 4M Net income 2025 * 7M EV / Sales 2024 * 2.53 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 2.11 x
P/E ratio 2024 *
18.3 x
P/E ratio 2025 *
11.2 x
Employees 35
Yield 2024 *
-
Yield 2025 *
-
Free-Float 78.4%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.49%
1 week-3.81%
Current month-2.21%
3 months+43.24%
6 months+133.48%
Current year+124.58%
More quotes
1 week
5.00
Extreme 5
5.85
1 month
5.00
Extreme 5
6.55
Current year
2.36
Extreme 2.3648
6.55
1 year
1.79
Extreme 1.79
6.55
3 years
1.79
Extreme 1.79
15.25
5 years
1.76
Extreme 1.7603
15.25
10 years
1.76
Extreme 1.7603
15.25
More quotes
Managers TitleAgeSince
Founder 71 10-05-06
Chief Executive Officer 71 10-05-06
Director of Finance/CFO 52 14-12-31
Members of the board TitleAgeSince
Chief Executive Officer 71 10-05-06
Director/Board Member 71 16-07-20
Director/Board Member 77 15-09-30
More insiders
Date Price Change Volume
24-06-14 5.3 -1.49% 90,482
24-06-13 5.38 -1.28% 568,324
24-06-12 5.45 -4.39% 196,049
24-06-11 5.7 +4.01% 144,401
24-06-10 5.48 -0.54% 297,623

Delayed Quote Nasdaq, June 14, 2024 at 04:00 pm EDT

More quotes
Sensus Healthcare, Inc. is a medical device company. The Company is focused on providing non-invasive treatments for both oncological and non-oncological skin conditions. The Company uses a low-energy X-ray technology known as superficial radiation therapy (SRT). The Company incorporated SRT into its portfolio of treatment devices: the SRT-100, SRT-100+ and SRT-100 Vision. SRT-100, is a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. Its SRT-100+ offer remote diagnostics solutions, including operation tracking.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
5.3 USD
Average target price
10 USD
Spread / Average Target
+88.68%
Consensus